LISATA THERAPEUTICS, INC. cotiza a 1.05 USD y tiene una capitalización bursátil de $11M. En los últimos 12 meses ha facturado $100000 con un margen de flujo de caja libre del -9398.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as …
| Periodo | 2026-11 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | — | $-0.49 | $-0.54 | $-0.55 |
| Estimado | — | $-0.53 | $-0.65 | $-0.53 |
| Sorpresa | — | +7.5% | +16.9% | -3.8% |
| Métrica | LSTA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -10711.2% | -38.6% | -10672.6% |
| Net Margin | -9756.5% | -33.6% | -9722.9% |
| FCF Margin | -9398.2% | -13.9% | -9384.4% |
| ROE | -111.7% | -40.4% | -71.3% |
| ROA | -93.5% | -32.0% | -61.5% |
| Current Ratio | 5.76 | 2.84 | +2.92 |
| Debt / Equity | — | 0.28 | — |